Compare Boston Scientific Corporation (BSX) vs NEOS S&P 500 High Income ETF (SPYI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs NEOS S&P 500 High Income ETF — how do they compare? Boston Scientific Corporation trades at $51.12 (market cap $71.46B), while NEOS S&P 500 High Income ETF trades at $54.19. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | SPYI | |
|---|---|---|
Market Cap | $71.46B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $54.19 |
52-Week Low | $42.63 | $47.98 |
Enterprise Value | $83.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
SPYI trades at $54.18, up 0.39% today, with a bullish technical signal driven by moving averages. The ETF focuses on generating high income through an options overlay on the S&P 500, offering monthly dividends. Recent news highlights its role in retirement income strategies, though some articles caution about yield sustainability.
The outlook hinges on volatility-driven income generation, with potential for steady returns if market conditions persist. Risks include declining volatility reducing payouts and principal erosion concerns. Investors should weigh the high yield against the strategy's dependency on options premiums.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →
